18-fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: A case series

BMC Pulmonary Medicine

Volumn 13, Issue 1, 2013, Pages

  Heysell, Scott K ^a   Thomas, Tania A ^a   Sifri, Costi D ^a,b   Rehm, Patrice K ^a   Houpt, Eric R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Multidrug resistant tuberculosis; Positron emission tomography; Pulmonary nodule; Tuberculosis

Indexed keywords

4 AMINOBENZOIC ACID; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; PYRAZINAMIDE;

ARTICLE; BACTERIUM CULTURE; BRONCHIECTASIS; CANCER STAGING; CASE REPORT; CASE STUDY; COUGHING; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FATIGUE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG LOBECTOMY; LUNG NODULE; LUNG TUBERCULOSIS; LYMPH NODE BIOPSY; MALE; MEDIASTINUM LYMPHADENOPATHY; POSITRON EMISSION TOMOGRAPHY; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION;

AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84875128441     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-13-14     Document Type: Article

References (19)

1. Lillington GA, Caskey CI. Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med 1993, 14:111-119.
2. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004, 34(4):313-329.
3. Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET/CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J 2010, 100:598-601.
4. Malik K, Dedhia HV, Bishop H. Clinical utility of PET-FDG imaging in detecting malignancy in pulmonary lesions. Chest 1996, 110(suppl):95S.
5. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18-Fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003, 124:893-901.
6. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000, 216:117-121.
7. Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, Ishizaki T, Fujibayashi Y, Okazawa H. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 2009, 36:632-639.
8. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, Desarnaud S, Doucet-Populaire F, Boué F. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis 2012, 16(9):1180-1185.
9. Soussan M, Brillet PY, Mekinian A, Khafagy A, Nicolas P, Vessieres A, Brauner M. Patterns of pulmonary tuberculosis on FDG-PET/CT. Eur J Radiol 2012, 81(10):2872-2876.
10. Treglia G, MD, Taralli S, Calcagni ML, Maggi F, Giordan A, Bonomo L. Is there a role for fluorine 18-fluorodeoxyglucose positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. J Comput Assist Tomogr 2011, 35:387-393.
11. Kim IJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S, Nam HY, Kim JS. Double phase 18 F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 2008, 35:808-814.
12. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Reviews 2009, 7:845-855.
13. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol 2010, 185:15-22.
14. Via LE, Schimel D, Weiner DM. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [18 F]2-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography. Antimicrob Agents Chemother 2012, 56(8):4391.
15. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
16. Tian G, Xiao Y, Chen B, Xia J, Guan H, Deng Q. FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis. Acta Radiologica 2010, 9:1002-1006.
17. Kim SJ, Kim IJ, Suh KT, Kim YK, Lee JS. Prediction of residual disease of spine infection using F-18 FDG PET/CT. Spine 2009, 34:2424-2430.
18. Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C. Use of 18 F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med 2011, 52:880-885.
19. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Noninvasive pulmonary [18 F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 2009, 53:4879-4884.